The stock of Zai Lab Limited ADR (ZLAB) has seen a 14.75% increase in the past week, with a 40.82% gain in the past month, and a 16.85% flourish in the past quarter. The volatility ratio for the week is 2.64%, and the volatility levels for the past 30 days are at 4.43% for ZLAB. The simple moving average for the past 20 days is 24.53% for ZLAB’s stock, with a 44.11% simple moving average for the past 200 days.
Is It Worth Investing in Zai Lab Limited ADR (NASDAQ: ZLAB) Right Now?
ZLAB has 36-month beta value of 0.98. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ZLAB is 108.40M, and currently, short sellers hold a 4.71% ratio of that float. The average trading volume of ZLAB on June 12, 2025 was 1.15M shares.
ZLAB) stock’s latest price update
Zai Lab Limited ADR (NASDAQ: ZLAB) has seen a rise in its stock price by 3.50 in relation to its previous close of 40.00. However, the company has experienced a 14.75% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-06-02 that SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating zocilurtatug pelitecan, or ZL-1310, the Company’s potential first-in-class, Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for patients with extensive-stage small cell lung cancer (ES-SCLC), will be presented today during a poster session at the 2025 American Society of Clinical Oncology (AS.
Analysts’ Opinion of ZLAB
Many brokerage firms have already submitted their reports for ZLAB stocks, with Scotiabank repeating the rating for ZLAB by listing it as a “Sector Outperform.” The predicted price for ZLAB in the upcoming period, according to Scotiabank is $55 based on the research report published on March 07, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see ZLAB reach a price target of $36.10, previously predicting the price at $29. The rating they have provided for ZLAB stocks is “Neutral” according to the report published on March 03rd, 2025.
Morgan Stanley gave a rating of “Overweight” to ZLAB, setting the target price at $47.50 in the report published on December 14th of the previous year.
ZLAB Trading at 30.30% from the 50-Day Moving Average
After a stumble in the market that brought ZLAB to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 3.09% of gains for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZLAB starting from Chen Yajing, who sale 9,618 shares at the price of $30.00 back on Jun 02 ’25. After this action, Chen Yajing now owns 17,429 shares of Zai Lab Limited ADR, valued at $288,540 using the latest closing price.
Chen Yajing, the Officer of Zai Lab Limited ADR, proposed sale 9,618 shares at $30.00 during a trade that took place back on Jun 02 ’25, which means that Chen Yajing is holding shares at $288,540 based on the most recent closing price.
Stock Fundamentals for ZLAB
Current profitability levels for the company are sitting at:
- -0.64 for the present operating margin
- 0.63 for the gross margin
The net margin for Zai Lab Limited ADR stands at -0.6. The total capital return value is set at -0.31. Equity return is now at value -32.05, with -23.32 for asset returns.
Based on Zai Lab Limited ADR (ZLAB), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -0.97. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -80.56.
Currently, EBITDA for the company is -234.57 million with net debt to EBITDA at 2.39. When we switch over and look at the enterprise to sales, we see a ratio of 10.24. The receivables turnover for the company is 4.77for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.26.
Conclusion
To put it simply, Zai Lab Limited ADR (ZLAB) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
